Non-Small Cell Lung Cancer (NSCLC)

Patients with EGFR-mutated non–small cell lung cancer who were treated with ado-trastuzumab emtansine and osimertinib experienced minimal anti-tumor outcomes.

Previously platinum-treated patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer saw clinical activity with mobocertinib regardless of prior PD-1/PD-L1 inhibitor history.

Durable efficacy and a manageable safety profile were observed with selpercatinib for Chinese patients with advanced, RET fusion–positive non–small cell lung cancer.

For patients with KRAS G12C–mutated non–small cell lung cancer and stable brain metastases who were previously treated with either radiation or surgery, robust anticancer activity was observed with intracranial complete responses and continued intracranial stabilization with sotorasib.

Patients with EGFR-positive non–small cell lung cancer whose disease is not suitable for standard EGFR TKI monotherapy had promising responses and experienced few dose-limiting toxicities with pelcitoclax plus osimertinib.

Patients with stage IIIB and stage IV advanced squamous non–small cell lung cancer experienced a clinically significant improvement in progression-free survival with tislelizumab plus chemotherapy in the first-line setting compared with standard of care chemotherapy.

Data from the ARROW study demonstrated safety and efficacy of pralsetinib in a cohort of Chinese patients with RET fusion–positive non–small cell lung cancer.

In a phase 1/2 trial, the selective targeting of EGFR exon 20 insertion mutations with mobocertinib in patients with previously treated non–small cell lung cancer resulted in superior patient-reported outcomes.

Findings from the phase 2 NRG-LU001 trial indicated that the addition of metformin to radiotherapy did not improve survival outcomes in patients with non–small cell lung cancer.

A 3-arm randomized study indicated that domvanalimab-based combinations yielded a promising overall response rate for patients with metastatic non–small cell lung cancer with a PD-L1 status of 50% or more.

The use of hypofractionated image-guide radiotherapy was not found to improve overall survival for patients with non–small cell lung cancer and poor performance status versus conventional fractionated radiation techniques.

Veterans diagnosed with stage I non–small cell lung cancer who have experienced delays in their surgical treatment over the past 12 weeks are at a higher risk of negative disease outcomes compared with those receiving surgery immediately after diagnosis.

Black patients with non–small cell lung cancer were more likely to be diagnosed at advanced stages of disease, less likely to receive surgery in early stages, and had increased cancer mortality rates than White patients.

Investigators advise against the use metformin in addition to chemoradiotherapy for patients with locally advanced non–small cell lung cancer due to progression-free survival and overall survival was not substantial.

Results of the phase 3 EMPOWER-Lung 3 trial support the use of cemiplimab in advanced or metastatic non–small cell lung cancer.

Patients with EGFR wild-type non–small cell lung cancer experienced a survival benefit with the addition of plinabulin to docetaxel in the second- and third-line settings.

Atezolizumab, which previously demonstrated positive results in the IMpower010 trial, was granted a priority review by the FDA for use in non–small cell lung cancer.

For patients with pIIIA-N2 non–small cell lung cancer, postoperative radiotherapy after complete resection and adjuvant chemotherapy did not positively impact disease-free survival.

CancerNetwork® sat down with Jorge Nieva, MD, at the 2021 ASCO Annual Meeting to talk about the future of clinical trials for early-stage non–small cell lung cancer.

Patients with non–small cell lung cancer who were treated with durvalumab plus stereotactic body radiotherapy were found to have a major pathological response and was well tolerated among the population.

CancerNetwork® sat down with Jonathan Spicer, MD, PhD, at the 2021 American Society of Clinical Oncology Annual Meeting to talk about how communication across a multidisciplinary team was necessary to the success of neoadjuvant immunotherapy administration in CheckMate 816.

At ASCO 2021, CancerNetwork® spoke with Stephen Liu, MD, about his research on the ARROW trial and how these results might impact the treatment of patients with RET fusion–positive non–small cell lung cancer who are potential candidates for treatment with pralsetinib.

CancerNetwork® sat down with John Heymach, MD, PhD, at the 2021 American Society of Clinical Oncology Annual Meeting to talk adjuvant immunotherapy for recurrence-free survival in resected non–small cell lung cancer.

Sintilimab with gemcitabine plus platinum produced superior clinical benefit for patients with locally advanced or metastatic squamous cell non–small cell lung cancer when compared with gemcitabine plus platinum alone.

At ASCO 2021, Stephen Liu, MD, discussed his excitement for results of the IMpower010 trial of atezolizumab in patients with early-stage resected non–small cell lung cancer

Foundation Medicine announced the expanded indication for FoundationOne Liquid CDx as a companion diagnostic to identify MET exon 14 skipping mutations in metastatic non–small cell lung cancer.

At ASCO 2021, Stephen Liu, MD, talked about treating patients with EGFR-mutant non–small cell lung cancer in the post-osimertinib setting with the combination of amivantamab and Lazertinib.

Patients with KRAS-positive NSCLC being treated with rigosertib plus nivolumab demonstrated early efficacy of the combination in a phase 1/2a trial.

FoundationOne CDx, a comprehensive genomic profiling test, has been approved for use in conjunction with brigatinib to test for solid tumors in patients with ALK-positive NSCLC.

Phase 2 data showed just over half of patients given dual therapy had a major pathological response, compared to just 6.7% of those receiving durvalumab monotherapy.